Karolinska University Hospital signs agreement to run SAGA’s ultrasensitive liquid biopsy tests in-house

Press photo, Carin Tellström/Karolinska universitetssjukhuset

LUND, Sweden — /October 8, 2019/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces it has entered a “lab-in-lab” customer agreement with Karolinska University Hospital, Department of Pathology, serving the greater Stockholm healthcare region.  As part of the agreement, SAGA is deploying its proprietary technology within the Karolinska molecular pathology laboratory, who will then use SAGA’s approach for tissue and liquid biopsy testing in samples from patients with non-small lung cancer (NSCLC).

“Partnering with Karolinska, now SAGA’s third major hospital system adopting our technology as a so-called lab-in-lab setup, is further proof of the growing interest in our ultrasensitive kits and services.  We are pleased to be establishing our technology in more laboratories worldwide, to allow ultrasensitive analyses to reach more people sooner.”

Åke Nilsson, Director of Corporate and Business Development at SAGA Diagnostics

Lung cancer, with 1.2 million new diagnoses per year worldwide, is in need of improved ultrasensitive diagnostics to monitor patients and identify DNA mutations that can help determine optimal therapy choice. Due to the location of tumors near vital organs, conventional tissue biopsy can be challenging and risky. Moreover, therapy-resistance is common and monitoring for the evolution of mutations during patient follow-up is desirable. For these reasons, an easy blood sample-based genomic test may offer advantages to the patient and caregivers.

“Karolinska is one of Europe’s premier health facilities and also one of it’s largest university hospitals.  We look forward to growing our cooperation with Karolinska in lung cancer and other cancer types.” 

Lao Saal, CEO, SAGA Diagnostics

SAGA’s technology for ultrasensitive detection of circulating tumor DNA (ctDNA) and gene mutations is rapid and cost effective. Within a core laboratory, a test can go from sample to result within the same day. Moreover, SAGA offers industry-leading performance to a lower limit of detection of ~0.001% mutant allele fraction, which is approximately 100-fold improved over competing approaches.

Contact: BD Director, Åke Nilsson,   ake.nilsson@sagadiagnostics.com   Phone: +46 (0)733 – 01 72 42

About SAGA Diagnostics

SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and provides the basis for optimal decision-making.

For more information please contact us, and follow us on Twitter @SAGAdiagnostics and LinkedIn.